Isomorphic Closes $2.1B Series B, Second Biggest Biotech
Alphabet's Isomorphic Labs closed a $2.1B Series B, the second biggest biotech fundraise ever, with no pipeline molecule disclosed.
Alphabet's Isomorphic Labs closed a $2.1B Series B, the second biggest biotech fundraise ever, with no pipeline molecule disclosed.
Telkom Indonesia's 140 sham transactions have drawn both SEC and DOJ scrutiny, spanning revenue recognition, internal controls, and FCPA compliance.
FCA's second AI Live Testing cohort puts agentic payments at Barclays, Lloyds and UBS under regulator watch. Mills Review reports this summer.
SEC's 2026 priorities make AI explainability an exam item across advisers and broker-dealers. Black-box LLM compliance tools don't produce the trail.
Brussels pushed AI Act high-risk rules to December 2027, lifting a 14-week cliff off credit-scoring and fraud teams. €15M penalty cap stays.
FinCEN's 7 April NPRM rewrites 25 years of AML rules. Buried in the fact sheet: AI use will weigh on how the Director sets fines.
FCA fined Wood Group £12.99M for accounting 'influenced by its desire to maintain prior results.' Shares had already cratered 78%.
The SECURE Data Act would replace the state privacy patchwork with one federal standard for businesses above $25M revenue and 200,000 consumers.
Colorado's SB 26-189 narrowed AI compliance scope for most deployers, then erased every federal exemption and put banks and insurers back in scope.
ChatGPT 4o told 19-year-old Sam Nelson the Kratom-Xanax mix was his 'best move,' and he died; OpenAI and Altman now face punitive damages.
ICO cut South Staffordshire's £963,900 fine by 40%, yet the breach ran undetected for 20 months while Cl0p ransomware exfiltrated 664k records.
Instructure settled with ShinyHunters after a 275-million-record breach, but security researchers warn ransoms don't guarantee deleted data.
FinCEN's AML overhaul rewards AI deployment as a mitigating factor. FCA still wants the algorithm explained. Same compliance team, two scripts.
Alkermes' Lumryz cleared a new Phase 3 in narcolepsy, putting the already-approved drug on a path toward a supplemental NDA filing.
The FCA stays tech-agnostic on AI in AML, but outcomes-based supervision means MLROs own the audit trail for every algorithmic call.